Pfizer announces termination of proposed combination with Allergan
- Details
- Category: Pfizer
Pfizer Inc. (NYSE: PFE) announced that the merger agreement between Pfizer and Allergan plc (NYSE: AGN) has been terminated by mutual agreement of the companies. The decision was driven by the actions announced by the U.S. Department of Treasury on April 4, 2016, which the companies concluded qualified as an “Adverse Tax Law Change” under the merger agreement.
Johnson & Johnson announces launch of new global public health strategy at opening of new operations in Africa
- Details
- Category: Johnson & Johnson
Johnson & Johnson today announced the official launch of its global public health strategy at the opening of its companies' on-the-ground global public health operations in Cape Town, South Africa.
Saxenda® demonstrated significant improvements in cardiometabolic risk factors over three years compared with placebo
- Details
- Category: Novo Nordisk
Today, new data from the three-year part of the phase 3a SCALE™ (Satiety and Clinical Adiposity - Liraglutide Evidence) Obesity and Prediabetes trial were presented at the Endocrine Society's 98th Annual Meeting and Expo (ENDO 2016).
World's first public dengue immunization program starts in the Philippines
- Details
- Category: Sanofi
Sanofi and its vaccines global business unit Sanofi Pasteur announced today that the first public dengue immunization program has started in the Philippines. At a major launch event, hosted by the Department of Health (DoH) of the Philippines,
Pandemic influenza vaccine receives positive CHMP opinion
- Details
- Category: AstraZeneca
AstraZeneca and its global biologics research and development arm, MedImmune, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the conditional approval of Pandemic Live Attenuated Influenza Vaccine (P/LAIV).
Brilinta preferred over clopidogrel in updated American College of Cardiology and American Heart Association guideline in acute coronary syndrome
- Details
- Category: AstraZeneca
AstraZeneca today confirmed that the American College of Cardiology (ACC) and American Heart Association (AHA) have released a treatment guideline on the duration of dual antiplatelet therapy (DAPT). Brilinta (ticagrelor) is now preferred over clopidogrel for the management of patients with acute coronary syndrome (ACS) who have received a coronary stent and in non-ST Elevation Acute Coronary Syndrome (NSTE-ACS) patients treated with medical therapy alone (Class IIa LoE: B-R).
Bristol-Myers Squibb and Pfizer announce global real-world data program and present new analyses of Eliquis (apixaban)
- Details
- Category: Pfizer
Bristol-Myers Squibb Company (NYSE: BMY) and Pfizer Inc. (NYSE: PFE) announced today that 17 abstracts will be presented at the American College of Cardiology's 65th Annual Scientific Session (ACC.16), to be held April 2-4 in Chicago, IL.
More Pharma News ...
- Boehringer Ingelheim launches RE-COVERY DVT/PE™: global observational study on management of Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) with Pradaxa® (dabigatran etexilate)
- Bristol-Myers Squibb to acquire Padlock Therapeutics, Inc.
- AstraZeneca reports top-line results from the Brilinta SOCRATES trial in stroke
- Amgen and UCB announce positive top-line tesults from phase 3 study evaluating romosozumab In men with osteoporosis
- Abbott's Absorb, the first fully dissolving heart stent, earns positive review by FDA advisory committee
- Pfizer celebrates a year of achievements in 2015 annual review
- FDA grants Roche's Cancer Immunotherapy Atezolizumab priority review for advanced bladder cancer